Sagar Lonial, MD, FACP

Editor-in-Chief

Sagar Lonial, MD, FACP, is Chair and Professor in the Department of Hematology and Medical Oncology, the Anne and Bernard Gray Family Chair in Cancer, and Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine in Atlanta, Georgia.

Dr. Lonial, who has authored or coauthored more than 200 peer-reviewed publications, is “internationally recognized as a leading authority in multiple myeloma treatment and research,” according to his biography from the Winship Cancer Institute.

He is a member of the Society of Hematologic Oncology (SOHO) Board of Directors and Chair of the SOHO Education Committee. Dr. Lonial is also involved with numerous other professional organizations.

Articles by Sagar Lonial, MD, FACP

Myeloma Panel Discusses the Latest CAR-T Treatment Data

Sagar Lonial, MD, FACPVideo Insights | September 19, 2023

In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.

2023 Midyear Highlights: BCT Editorial Board Rounds Up the News

Sagar Lonial, MD, FACPPrint | August 17, 2023

The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.

Sagar Lonial, MD, FACP, Talks Multiple Myeloma Highlights from the Summer Conferences

Sagar Lonial, MD, FACPMeeting News | June 9, 2023

Dr. Lonial shares his top highlights in multiple myeloma from the EHA and ASCO meetings.

What Do Harry Potter and Blood Cancers Have in Common?

Sagar Lonial, MD, FACPViewpoints | May 12, 2023

To quote a well-known exchange from the final Harry Potter movie, “it’s complicated.”

Panel Discusses Best Practices for Post-CAR-T Management with Local Health Care Teams

Thomas Martin, MDVideo Insights | May 2, 2023

The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.

Management of CAR-T Toxicities: CRS, Neurological, Cytopenias, Infection

Thomas Martin, MDVideo Insights | May 2, 2023

The panel discusses side effect management with CAR T-cell therapy.

Bispecific Versus CAR T-Cell Therapy for Myeloma, Bridging Therapy Needs for CAR-T

Thomas Martin, MDVideo Insights | May 1, 2023

The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.

Who Is the Right Patient for CAR-T Therapy?

Thomas Martin, MDVideo Insights | May 1, 2023

Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.

Frontline CAR-T Use and the 'Sweet Spot' for Treatment Sequencing

Thomas Martin, MDVideo Insights | April 28, 2023

The panel addresses the potential for frontline CAR-T use.

Moving CAR-T Therapy Earlier in the Myeloma Treatment Course

Thomas Martin, MDVideo Insights | April 28, 2023

The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.

Is There an Ideal Space for Allogeneic CAR-T Products for Myeloma?

Thomas Martin, MDVideo Insights | April 27, 2023

The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.

Dual-Targeting, Allogeneic CARs Are Options to ‘Keep Myeloma on its Toes’

Thomas Martin, MDVideo Insights | April 27, 2023

Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.

A Look at the CAR-T Pipeline: ddBCMA and LUMMICAR

Thomas Martin, MDVideo Insights | April 26, 2023

BCMA-targeted autologous CAR T-cell therapies are discussed.

Ciltacabtagene Autoleucel and CARTITUDE Findings in Relapsed/Refractory Myeloma

Thomas Martin, MDVideo Insights | April 26, 2023

The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.

Idecabtagene Vicleucel for Myeloma: KarMMa Study Results and Real-World Evidence

Thomas Martin, MDVideo Insights | April 25, 2023

Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.

Spotlight on BCMA: A Major Target for Multiple Myeloma

Thomas Martin, MDVideo Insights | April 24, 2023

In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.

Sagar Lonial, MD, FACP, on Multiple Myeloma Awareness Month

Sagar Lonial, MD, FACPMyeloma | March 6, 2023

Sagar Lonial, MD, FACP, Editor-in-Chief of Blood Cancers Today, discusses Multiple Myeloma Awareness Month.

Striving with Humility and Grace in the New Year

Sagar Lonial, MD, FACPPrint | December 22, 2022

The past few years have been more than a challenge for those of us in health care, but we have learned many lessons.

The HemOnc Pulse Live at ASH: Sagar Lonial, MD, FACP, on Role of Transplant, MRD in Myeloma

Chadi Nabhan, MD, MBA, FACPMyeloma | December 14, 2022

Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses novel therapies in myeloma, MRD data, and more.

Making Medical Strides, Despite Socioeconomic and Cultural Setbacks

Sagar Lonial, MD, FACPPrint | June 23, 2022

ASCO, EHA, and other medical society meetings represent the best of who we are—people working together toward a common ...